Swiss drug major Novartis AG (NVS) announced Tuesday that its eye care division Alcon will highlight its vision, strategy and benefits as a standalone company following the planned spinoff.
瑞士制药巨头诺华公司（ Novartis AG ）周二宣布，其眼保健部门爱尔康（ Alcon ）将在计划分拆后，作为一家独立的公司，突出其愿景、战略和效益。
Alcon will today hold its first Capital Markets Day for investors and analysts in relation to Novartis' intention to execute a tax-neutral, 100% spinoff of the Alcon business. If the transaction proceeds, shares in Alcon Inc. will be listed on the SIX Swiss Exchange and the New York Stock Exchange under the ticker symbol "ALC".
美国铝业今天将为投资者和分析人士举办首个资本市场日，内容是诺华打算将美国铝业的业务剥离出去，实现不含税的100%。如果交易继续进行，美国铝业公司的股票将在瑞士证券交易所和纽约证券交易所上市，股票代码为“ ALC ”。
Chairman-designate, Mike Ball and CEO, David Endicott, will be joined by other senior management to discuss Alcon's strengths and how the company is positioned to win in the large, attractive and growing eye care devices market.
董事长兼指定人 Mike Ball 和首席执行官 David Endicott 将与其他高级管理人员一起讨论爱尔康的优势，以及该公司在大型、有吸引力和不断增长的眼部护理设备市场上的优势。
They will present Alcon's vision and strategy, near-and longer-term growth drivers, five-year financial goals and the benefits of Alcon as a standalone company.
他们将介绍爱尔康的愿景和战略、近期和长期的增长动力、五年的财务目标以及作为独立公司的爱尔康的好处。
Alcon will highlight mega-trends shaping the future of eye care. These trends present Alcon with sizeable growth opportunities in the $23 billion eye care devices market.
爱尔康将突出塑造眼部护理未来的巨大趋势。这些趋势给爱尔康带来了230亿美元眼部护理设备市场可观的增长机会。
CFO David Murray will highlight how the company plans to make steady core operating margin improvements to industry benchmark levels, from high teens today to low to mid 20s by 2023.
首席财务官戴维•默里( David Murray )将重点介绍该公司计划如何在行业基准水平上稳步提高核心营运利润率，从现在的青少年到2023年的20岁中期。
Post-spinoff, Alcon is targeting an investment grade credit rating and will have a financial framework focused on sales growth, operational excellence and free cash flow generation.
剥离后，爱尔康的目标是投资级别的信用评级，并将有一个财务框架集中于销售增长、运营卓越和自由现金流产生。
David Endicott, CEO of Alcon, said: "As the leading eye care devices company in the world, with $6.8 billion in sales in 2017, we are uniquely positioned to succeed as a standalone organization."
爱尔康首席执行官大卫•恩迪科特( David Endicott )表示：“作为全球领先的眼部护理设备公司，2017年销售额达68亿美元，我们在作为独立机构成功方面处于独特的地位。”
The company noted that completion of the planned spinoff is subject to general market conditions, receipt of necessary authorizations, tax rulings and opinions, final endorsement by the Board of Directors of Novartis and shareholder approval at the Novartis annual shareholder meeting on February 28, 2019.
公司注意到，本次拟分拆完成尚需满足一般市场条件、收到必要的授权、税务裁决和意见、诺华董事会最终认可并在2019年2月28日召开的诺华年度股东大会上获得股东批准。
If approvals are secured and conditions are met, the spinoff is expected to be completed in the first half of 2019.
如果获得批准并满足条件，预计分拆将于2019年上半年完成。
内容来源：RTTNews
机器翻译：商鹊网